Moleculin biotech, inc. (MBRX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15
Cash flows from operating activities:
Net loss

-10,373

-13,205

-12,193

-10,086

-13,990

-11,876

-12,276

-13,103

-11,403

-9,805

-8,043

-6,609

-3,923

-3,926

-3,027

-1,819

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

197

199

188

150

108

68

32

25

22

18

17

13

10

6

2

1

0

0

0

Stock-based compensation

1,586

1,537

1,470

1,225

1,246

1,140

1,045

1,069

839

707

602

381

432

324

209

162

0

0

0

Deferred compensation - related party

-

-

-

-

-

-

-

-

-

62

61

150

125

87

0

0

0

-

-

Gain from change in fair value of warrant liability

-7,378

-4,062

-4,630

-5,081

-3,005

-3,185

0

0

0

-

-

-

-1,059

0

0

0

0

-

-

Operating lease, net of sublease receipts

-85

14

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain in settlement of liability

-

-

-

-

-

-

-

-

-

149

149

149

149

0

0

0

0

-

-

Shares issued for licenses used for research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

1,307

1,909

2,417

337

197

252

18

351

355

364

488

495

270

215

0

0

0

-

0

Accounts payable

-1,593

907

2,403

-419

2,228

436

-131

1,285

-115

411

0

0

0

-

-

-

-

-

-

Accrued expenses and other current liabilities

601

-1,140

-964

-634

301

1,400

1,650

1,584

597

495

0

0

0

-

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

112

-99

0

0

0

Net cash used in operating activities

-17,693

-17,198

-15,631

-15,123

-13,243

-12,203

-11,483

-10,275

-8,740

-7,324

0

0

0

-

-

-

-

-

-

Accounts payable and accrued expenses - related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net Cash Used in Operating Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,068

0

0

0

Cash flows from investing activities:
Investment in note receivable - Moleculin, LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Purchase of fixed assets

39

52

156

443

424

417

319

32

36

28

0

0

0

-

-

-

-

0

0

Acquisition of Moleculin, LLC, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net cash used in investing activities

-38

-51

-156

-443

-424

-417

-319

-32

-36

-28

0

0

0

-

-

-

-

-

-

Net Cash Used in Investing Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

Cash flows from financing activities:
Proceeds from exercise of stock options

0

5

10

10

10

5

0

0

0

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of common stock, net of issuance costs

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

165

365

615

0

0

0

Payments on notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Proceeds from exercise of warrants

-

-

-

-

-

15

195

871

3,198

3,988

0

0

0

-

-

-

0

-

-

Proceeds from sale of common stock, net of issuance costs

-

-

-

-

-

12,025

0

0

0

-

-

-

-

-

-

9,168

0

0

0

Proceeds from sale of common stock units, net of cash stock issuance costs

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

Net cash provided by financing activities

20,624

20,854

22,615

22,563

9,351

12,045

11,668

12,751

13,009

10,059

0

0

0

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-26

-4

-19

-24

-16

-5

0

0

0

-

-

-

-

-

-

-

-

-

-

Net change in cash and cash equivalents

2,867

3,601

6,809

6,973

-4,332

-580

0

0

0

-

-

-

-

-

-

-

-

-

-

Net Cash Provided by Financing Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,313

0

0

0

Net change in cash and cash equivalents

-

-

-

-

-

-

-

-

-

2,707

2,552

2,027

8,621

4,979

6,096

7,245

0

0

0

Supplemental disclosures of cash flow information:
Cash paid for interest

0

1

3

5

5

5

0

0

0

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-43

5

5

48

48

0

0

0

Cash paid for taxes

23

19

16

17

18

21

20

15

5

0

0

0

0

0

0

0

0

0

0

Non-cash investing and financing activities:
Purchases of property and equipment in accounts payable and accrued liabilities

4

22

-92

44

64

23

0

0

0

-

-

-

-

-

-

-

-

-

-

Common stock issued for the Acquisition of Moleculin, LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Common stock issued for conversion of debt

-

-

-

-

-

-

-

-

-

302

324

465

554

364

342

201

0

0

0

Common stock issued for services provided

-

-

-

-

-

-

-

-

-

89

247

247

247

158

0

0

0

-

-

Shares subscribed

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0